The FDA has approved a supplementary ANDA for oral atorvastatin calcium by Cipla USA Inc., allowing the company to expand its generic cholesterol-lowering offerings. This clearance is expected to bolster Cipla's market competitiveness and increase accessibility to this widely prescribed therapeutic.